| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2473431 | Current Opinion in Virology | 2011 | 8 Pages |
The safety, stability, and ability for repeat homologous vaccination makes the DNA vaccine platform an excellent candidate for an effective HIV-1 vaccine. However, the immunogenicity of early DNA vaccines did not translate from small animal models into larger non-human primates and was markedly lower than viral vectors. In addition to improvements to the DNA vector itself, delivery with electroporation, the inclusion of molecular adjuvants, and heterologous prime-boost strategies have dramatically improved the immunogenicity of DNA vaccines for HIV and currently makes them a leading platform with many areas warranting further research and clinical development.
► HIV-specific cellular and humoral immune responses are improved by delivering HIV-DNA vaccines with electroporation. ► Co-immunization of a HIV-DNA vaccine with molecular adjuvants can modulate HIV-specific immune responses. ► Heterologous prime-boost strategies with DNA and viral vectors or recombinant protein outperform any single platform.
